Review Not peer-reviewed version

Advances in Encapsulating Marine

Bioactive Compounds Using
Nanostructured Lipid Carriers (NLC) and
Solid Lipid Nanoparticles (SLN) for
Health Applications

Rita Favas , Hugo Almeida , Andreia F. Peixoto , Domingos Carvalho Ferreira , Ana Catarina Silva *

Posted Date: 22 October 2024

doi: 10.20944/preprints202410.1622.v1

Keywords: healthcare; cosmetics; food supplements; marine bioactive compounds; lipid nanoparticles

Preprints.org is a free multidisciplinary platform providing preprint service

that is dedicated to making early versions of research outputs permanently
available and citable. Preprints posted at Preprints.org appear in Web of
Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0
license, which permit the free download, distribution, and reuse, provided that the author
and preprint are cited in any reuse.
Preprints.org (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 October 2024 doi:10.20944/preprints202410.1622.v1

Disclaimer/Publisher’s Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and
contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting
from any ideas, methods, instructions, or products referred to in the content.

Review

Advances in Encapsulating Marine Bioactive

Compounds Using Nanostructured Lipid Carriers
(NLC) and Solid Lipid Nanoparticles (SLN) for
Health Applications
R. Favas1,2, H. Almeida1,2,3, A.F. Peixoto 4, D. Ferreira1,2, A.C. Silva1,2,5,*
1 UCIBIO, Laboratory of Pharmaceutical Technology, Faculty of Pharmacy, University of Porto, Porto,
Portugal
2 Associate Laboratory i4HB Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto,

Porto, Portugal
3 Mesosystem Investigação & Investimentos by Spinpark, Guimarães, Portugal.

3 LAQV-REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do

Porto, Porto, Portugal

5 FP-I3ID (Instituto de Investigação, Inovação e Desenvolvimento), FP-BHS (Biomedical and Health Sciences

Research Unit), Faculty of Health Sciences, University Fernando Pessoa, Porto, Portugal
* Correspondence: author: [email protected]

Abstract: With increased life expectancy and improved modern lifestyles, there has been a growing
concern for health, including the prevention of disease and the improvement of physical
appearance. Consumers are increasingly aware of the benefits of using natural ingredients in
healthcare products and at the same time are concerned about the challenges of sustainability. In
this sense, the use of marine bioactive compounds as cosmetic ingredients and in food supplements
has become increasingly popular due to the benefits derived from their various properties.
However, some of these compounds have limited use, mainly due to their low stability and poor
aqueous solubility, and solutions need to be developed to overcome these limitations. In this sense,
the use of lipid nanoparticles, such as solid lipid nanoparticles (SLN) and nanostructured lipid
carriers (NLC), has been explored as these carriers show ability to protect and enhance the
absorption of molecules. Several studies have demonstrated the efficacy of encapsulating these
compounds and incorporating them into cosmetics and food supplements. However, there is still
no global legislation and safety concerns have been raised. Further clinical studies in animals and
humans are needed to clarify safety issues.

Keywords: healthcare; cosmetics; food supplements; marine bioactive compounds; lipid

nanoparticles

1. Introduction
With increasing life expectancy and modern lifestyles, there is a growing concern for health,
including the prevention of diseases and the improvement of physical appearance. Consumers are
realizing the benefits of using natural compounds in health products. [1]
The marine ecosystem provides a rich source of active ingredients that can be incorporated into
cosmetics and food supplements. Among marine organisms, algae, crustaceans, bacteria and fungi
stand out as promising sources of bioactive compounds with different properties, such as
antimicrobial and antioxidant properties, which are promising at different stages of product
development, from processing to storage and formulation.[2] Within this vast source of bioactive
compounds are fatty acids, carotenoids and vitamins, each with a wide range of benefits.
Fatty acids are essential components of fats and oils, playing a crucial role in regulating various
physiological processes.[3] They are categorized as monounsaturated fatty acids (MUFAs) or

© 2024 by the author(s). Distributed under a Creative Commons CC BY license.

Preprints.org (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 October 2024 doi:10.20944/preprints202410.1622.v1

polyunsaturated fatty acids (PUFAs) based on their length, degree of unsaturation, and number of
bonds. PUFAs, particularly omega-3, are the predominant type of fatty acids found in the marine
environment and can be sourced from algae (especially red macroalgae), marine by-products, yeasts,
bacteria, and fungi, serving as alternative options to traditional seafood sources for human
consumption. [3,4]
Carotenoids are isoprenoid pigments with colors within the yellow-to-red spectrum and play a
crucial role in various physiological activities.[5] They are produced by all photosynthetic organisms
and obtained through diet by other organisms who cannot synthesize them.[6] Carotenoids are
categorized into two main groups based on their structure and chemical composition. The first group
includes the carotenes, hydrocarbons without oxygen, such as β-carotene and lycopene. The second
group includes the xanthophylls, which consist of oxygenated derivatives of carotenes, such as
astaxanthin, fucoxanthin, and zeaxanthin.[7]
Vitamins are crucial for proper metabolism and overall health. Because the body cannot produce
enough vitamins, humans must get them from food or supplements. Vitamins are classified based on
their properties, whether they are water-soluble or fat-soluble. While fat-soluble (i.e. lipophilic)
vitamins, such as A, D, E, and K, are easily stored upon absorption, water-soluble (i.e. hydrophilic)
vitamins, such as C and B, are washed out and not stored in the body.[8,9] Common sources of these
vitamins include fish, algae, bacteria, fungi, corals, sea cucumbers, and sponges.[10–13]
Various methods and carriers have been used in the cosmetic and food sector, such as
microparticles (i.e. microcapsules or microspheres) and colloidal carriers (e.g. liposomes,
nanoemulsions and lipid nanoparticles).[14] Due to the lipophilic nature of some of these bioactive
compounds, they cannot be incorporated into aqueous formulations. Encapsulation techniques have
therefore been explored to increase the solubility, stability, and activity of these compounds.[15] They
are used in the food industry to preserve components from environmental conditions, to mask
unpleasant tastes, or to extend shelf life.[16] In cosmetics they can improve skin hydration, epidermal
delivery and increase local compound concentration with less systemic absorption.[17] Although
microencapsulation has been extensively studied, nanoencapsulation techniques have been found to
resolve some limitations, leading to the production of more stable carriers that improve the
absorption and activity of bioactive molecules.[16] Among these, lipid nanoparticles are gaining
attention for their effectiveness in encapsulating, protecting and promoting the absorption of
lipophilic molecules.[15,18,19] Notwithstanding, other bioactive marine compounds, such as
polysaccharides and proteins, are being used to modify the surface of lipid nanoparticles.
Polysaccharides and proteins are important macromolecules in various living organisms and are
critical in promoting overall body function and balance. They serve as energy sources and are
essential for molecular recognition, defense, tissue formation, energy storage, and cellular
transport.[20–22] Polysaccharides are derived from different marine sources and can be categorized
into marine animal polysaccharides (i.e. chitin and chitosan), marine plant polysaccharides (i.e.
alginate), and marine microbial polysaccharides (i.e. glucan).[20,23,24] Fish and algae are the major
source of marine proteins, with the most interesting and useful being collagen and gelatin. These
polymers have been applied to increase the stability and compatibility of lipid nanoparticles in
different products and processes.[25]
This review aims to provide an overview of the state of the art in the use of marine bioactive
compounds encapsulated in lipid nanoparticles, namely nanostructured lipid carriers (NLC) and
solid lipid nanoparticles (SLN), in cosmetics and food supplements. Regulatory and safety aspects of
the use of this type of nanoparticles are also addressed.

2. Lipid Nanoparticles
Lipid nanoparticles are spherical particles composed of one or more lipids, with molecules
solubilized or dispersed in the matrix and are stabilized by emulsifying agents. Depending on their
internal structure and composition, these nanoparticles can be classified as solid lipid nanoparticles
(SLN) or nanostructured lipid carriers (NLC).[17,26,27]
Preprints.org (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 October 2024 doi:10.20944/preprints202410.1622.v1

SLN were first described and consist of one solid lipid (5-40%), one or two emulsifiers (0.5-5%),
the encapsulated molecules, and water (q.s. 100%). The use of solid lipids creates a matrix that
enhances physical-chemical stability and delays the release of the encapsulated molecules. The lipid
matrix remains solid at both body and room temperatures and acts as a protective barrier, protecting
the molecules from degradation caused by environmental factors such as light, heat, pH, and
enzymes. Being composed of physiological lipids (know as Generally Recognized as Safe - GRAS),
this type of lipid nanoparticles are biocompatible, exhibit good permeation through various body
tissues, and can be easily incorporated into a different pharmaceutical dosage forms for topical, oral
and parenteral administration.[19,26,27] However, SLN have limitations, mainly related to a low
capacity to encapsulate molecules in the lipid matrix and excessive crystallization of the lipids during
storage, leading to leakage of the encapsulated molecules. Thereby, more advanced nanocarriers
derived from SLN have been developed, the nanostructured lipid carriers (NLC), which consist of a
solid matrix resulting from the combination of a solid lipid and a liquid lipid, the former in a higher
percentage. Compared to SLN, NLC have been shown to have a higher loading capacity and a greater
ability to prevent the release of molecules during storage by inhibiting or reducing the crystallization
of lipids. These advantages have been attributed to the presence of the liquid lipid, which results in
a more disorganized lipid matrix with more space to accommodate molecules. [17,26–30]
Interested readers can consult the references provided for very comprehensive reviews of the
characteristics of SLN and NLC.

2.1. Relevant Studies with Bioactive Marine Compounds in SLN and NLC
Given the various applications of marine bioactive compounds in health care and the possibility
of encapsulating them in SLN and NLC to overcome their main limitations, the analysis of published
studies will provide good prospects for their potential use. Although most of the research focuses on
the encapsulation of these compounds, some studies also present information on their potential
health applications.
Additionally, marine bioactive compounds such as chitosan, alginate, and gelatin have been
tested as coating polymers to modify the surface of SLN and NLC. They can increase their stability,
performance, delivery efficiency, absorption rate and biocompatibility.[25] Table 1 provides a
summary of the key findings from the most relevant studies in this area.

Table 1. Relevant studies and applications of the main bioactive marine compounds
encapsulated in SLN and NLC.

Marine Type of Type

Healthcare
bioactive lipid of Relevant results References
application
compound nanoparticle study

Docosahexaenoic acid
Particle size: 100 ± 1.8
nm
PDI: 0.220 ± 0.020
Docosahexaenoic
In EE: 100% Food
and α-linolenic SLN [31]
vitro supplement
acid
α-linolenic acid
Particle size: 842.2 ± 1.3
nm
PDI: 0.126 ± 0.017
Preprints.org (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 October 2024 doi:10.20944/preprints202410.1622.v1

EE: 77%

Particle size: 163.7 ± 2.0

nm
In
ZP: 40.1 ± 1.3 mV
Docosahexaenoic vitro Food
NLC PDI: 0.118 ± 0.01 [32]
acid and in supplement
EE: 78.13 ± 1.85%
vivo
DL: 28.09 ± 0.48%
DPPH: 0.57 ± 0.03
Particle size: 222.8 ± 87.3
nm
ZP: -43.46 ± 1.74 mV
In
PDI: 0.666
vitro
EE: 23.96 ± 3.13% Cosmetic [33]
and in
34%
vivo
in vivo penetration of β–
carotene in deeper skin
β–carotene NLC layers in humans
Particle size: 166.3 ± 0.19
nm
ZP: -26.9 ± 0.17 mV
In PDI: 0.35 ± 0.1 Food
[34]
vitro EE: 91.2 ± 0.15% supplement
ABTS: 91.47 ± 1.9%
DPPH: 24.72 ± 0.38%
IC50: 7.0 μg/mL
Particle size: 67.4 ±
2.1nm
PDI: 0.26
EE: 94.3 ± 0.5%
In [35]
Astaxanthin NLC CR: 83.0 ± 3.4% at 48h Cosmetic
vitro
CP:174.10 ± 4.38
μg/cm[2]
Retention: 18.60 ± 1.62
μg/cm[2]
Preprints.org (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 October 2024 doi:10.20944/preprints202410.1622.v1

In vitro
Particle size: 114.4 nm
ZP: -34.1 mV
In EE: 85.67%
vitro ROS reduction: 81.6%
Cosmetic [36]
and in DNA damage
vivo reduction: 41.6%
In vivo
Protection of 6/6 mice
from skin damage
Particle size: 145.3 nm
ZP: -30.8 ± 0.3 mV
In PDI: 0.468 ± 0.036
[37]
vitro EE: 94.8 ± 1.0%
Stability: 28 days at
25ºC
Particle size: 142.8 ± 5.02 Food
nm supplement
In ZP: -32.2 ± 7.88 mV
vitro PDI: 0.247 ± 0.016
[38]
and in EE: 94.1 ± 2.26%
vivo DL: 23.5 ± 1.48%
Stability: 6 months at 4-
8 ± 2ºC
SLN
Particle size: 106.967 ±
2.515 nm
ZP: −24.133 ± 0.379
mV
PDI: 0.220 ± 0.017
SLN and In Food
EE: 99.99 ± 0.00% [39]
NLC vitro supplement
NLC
Particle size: 117.300 ±
2.163 nm
ZP: 23.267 ± 0.451 mV
PDI: 0.222 ± 0.016
EE: 99.61 ± 0.04%
Particle size: 166 ± 4 nm
In ZP: -74.6 ± 2.0 mV
Lycopene NLC Cosmetic [40]
vitro PDI: 0.15 ± 0.05
EE: 100 ± 0%
Preprints.org (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 October 2024 doi:10.20944/preprints202410.1622.v1

FRS: 36.6 ± 0.4mM/mg

NLC
AA: 14.1 ± 0.6mg/mL

Particle size: 427.3 ± 5.7

nm
ZP: 21.21 ± 1.23 mV
NLC [41]
In PDI: 0.309 ± 0.11
Fucoxanthin Cosmetic
vitro EE: 90.12 ± 2.51%
DL: 1.62 ± 0.12%
Particle size: 168 nm
SLN [42]
PDI: 0.162
Particle size: 224 nm
In PDI: 0.205
vitro Vitamin A
[43]
and ex concentration in the in
vivo the stratum corneum:
SLN 3400 ng Cosmetic
Particle size: 350 nm
In
DR: 54.38% up to 24h
vitro
Unabsorbed vitamin A: [44]
and in
67%
vivo
PII: 0.00
SLN
Vitamin A
Particle size: 223 ± 10
nm
ZP: -25 ± 1 mV
PDI: 0.171 ± 0.008
EE: 97 ± 3%
SLN and
DL: 7%
NLC In Food [45]
NLC
vitro supplement
Particle size: 228 ± 7 nm
ZP: -22 ± 1 mV
PDI: 0.146 ± 0.007
EE: 90 ± 1%
DL: 7%
Particle size: 87 ± 5 nm
In
ZP: -12.2 ± 4.86 mV [46]
vitro
PDI: 0.24 Food
Vitamin D NLC
Particle size: 110 ± 4 nm supplement
In
ZP: -17.10 ± 0.30 mV [47]
vitro
PDI: 0.23 ± 0.01
Preprints.org (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 October 2024 doi:10.20944/preprints202410.1622.v1

and in
vivo

In Particle size: 105 to 328

[48]
vitro nm
Particle size: 386 ± 0.00
nm [49]
In
NLC OF: 80% Cosmetic
vitro
Particle size: 82 nm
and in
ZP: -28.6 mV
Vitamin E vivo [50]
PDI: 0.261
EE: 95.83 ± 0.02%
Particle size: 228.2 ± 3.5
nm
In Food
SLN ZP: -8.92 ± 2.2 mV [51]
vitro supplement
PDI: 0.34 ± 0.02
EE: 99.9 ± 0.1%
Particle size: 132 nm
In ZP: -26.83 ± 2.83 mV Food
Vitamin K SLN [52]
vitro PDI: 0.17 ± 0.02 supplement
EE: 98%
Particle size: 231.5 ± 5.8
In
nm
vitro
Chitosan coating NLC PDI: 0.18 ± 0.01 Cosmetic [53]
and ex
ZP: 19.9 ± 0.3 mV
vivo
EE: 96%
Particle size: 321.2 ± 18.3
nm
PDI: 0.23 ± 0.02
In
Alginate coating NLC ZP: -16.0 ± 3.0 mV Cosmetic [54]
vitro
EE for quercetin: 85%
EE for alpha-
tocopherol: 92%
Particle size: 100.4 nm
In PDI: 0.36 Food
Gelatin coating NLC [55]
vitro ZP: -18.4 mV supplement
EE: 80%
Abbreviations: AA: antioxidant activity; ABTS: 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) assay; CP:
cumulative permeability; CR: cumulative release; DL: drug loading; DPPH: 2,2-diphenyl-1-pyridylohydrazinyl
assay; DR: drug release; EE: encapsulation efficiency; FRS: free radical scavenging; NLC: nanostructured lipid
carriers; OF: occlusion factor; PDI: polydispersity index; PII: primary irritation index; SLN: solid lipid
nanoparticles; ZP: zeta potential.
Preprints.org (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 October 2024 doi:10.20944/preprints202410.1622.v1

2.2 Omega 3
Research on SLN and NLC loaded with omega-3 mostly focuses on their use as a component of
the oil phase rather than as a bioactive compound. However, a few studies have explored the latest
application. For instance, Serini et al. encapsulated α-linolenic and docosahexaenoic acid in SLN. In
the experiments, the researchers evaluated the physiochemical properties of SLN and their effect on
human colorectal cancer cells (HT-29 and HCT116 cell lines). Regarding the docosahexaenoic acid
and α-linolenic acid encapsulation, the particle size was 100 ± 1.8 nm and 842.2 ± 1.3 nm, the
polydispersity index (PDI) was 0.220 ± 0.020 and 0.126 ± 0.017, and the encapsulation efficiency (EE)
was 100% and 77%, respectively. The results showed that after encapsulation, there was a significant
increase in the uptake of α-linolenic acid in cancer cells after 24 hours of incubation. The incorporation
of docosahexaenoic acid was also notably higher at 24 hours when encapsulated in the SLN. At all
tested concentrations, free docosahexaenoic acid and docosahexaenoic acid-loaded SLN
demonstrated a time-dependent inhibition of colorectal cancer cell growth. After 48 and 72 hours, the
50 μM docosahexaenoic acid-loaded SLN demonstrated a significantly greater inhibition of cell
growth (p < 0.01 and p < 0.001 in HT29 and HCT116 cells, respectively) compared to the free
docosahexaenoic acid at the same concentration. In addition, α-linolenic acid exhibited a significantly
inhibitory effect on the growth of HT-29 and HCT116 cells after 48 hours, with a more pronounced
effect observed after 72 hours. Notably, in HT-29 cells, α-linolenic acid-loaded SLN was significantly
more effective (p < 0.02) in inhibiting tumor cell growth than free α-linolenic acid at all the
concentrations tested. In HCT116 cells, α-linolenic acid-loaded SLN demonstrated significantly
enhanced efficacy than free α-linolenic acid at concentrations of 10 and 50 μM (p < 0.05 and p < 0.001,
respectively).[31]
The potential of using docosahexaenoic acid encapsulated in NLC for peri-implantitis treatment
was studied. The docosahexaenoic acid-loaded NLC had particle size of 163.7 ± 2.0 nm, PDI of 0.118
± 0.01, zeta potential (ZP) of 40.1 ± 1.3 mV, and EE of 78.13% ± 1.85%. The release of docosahexaenoic
acid from the NLC showed a gradual and steady pattern over 144 hours. According to the 2,2-
diphenyl-1-pyridylohydrazinyl (DPPH) assay in vitro studies, the free-radical-scavenging rate of the
docosahexaenoic acid-loaded NLC was significantly higher (0.57 ± 0.03) than that of pure
docosahexaenoic acid (0.17 ± 0.003, p < 0.001). Moreover, the docosahexaenoic acid-loaded NLC
exhibited a superior inhibitory effect on the expression of cellular inflammatory factors compared to
the pure form. In vivo studies on rats also showed that the docosahexaenoic acid-loaded NLC group
displayed the most effective suppression of gingival inflammation after a 2-week reagent
treatment.[32]

2.3. β–Carotene
In the study conducted by Maretti et al. on encapsulated β-carotene, two different NLC
formulations were prepared, with particle sizes ranging between 200 and 800 nm. The researchers
evaluated the skin penetration of these carriers in humans (n = 4) by measuring the concentration of
β-carotene in the stratum corneum. The results showed that pure β-carotene was mainly retained in
the outer layers of the stratum corneum (45%). In contrast, one of the β-carotene-loaded NLC
formulations demonstrated improved penetration into deeper skin layers, with 34% of β-carotene
detected. The characterization studies revealed that the -carotene loaded NLC were spherical and
showed a particle size of 222.8 ± 87.3 nm, PDI of 0.666, ZP of -43.46 ± 1.74 mV, and EE of 23.96 ±
3.13%.[33]
The application of β-carotene in the food industry was also investigated by Rohmah et al.. The
study aimed to evaluate the bioavailability and antioxidant activity of β-carotene-loaded NLC. For
the experiments, was used an in vitro gastrointestinal tract model to simulate the biological course
of ingested food through mouth, gastric, and intestinal phases. The particle size was 166.3 ± 0.19 nm,
the PDI was 0.35 ± 0.1, the ZP was -26.9 ± 0.17 mV, and the EE was 91.2 ± 0.15%. The results showed
that NLC have a superior capacity to encapsulate β-carotene compared to the other tested systems,
such as a β-carotene emulsion, a β-carotene-tween 80 phosphate buffered solution, and a β-carotene
Preprints.org (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 October 2024 doi:10.20944/preprints202410.1622.v1

and phosphate buffered solution (p < 0.05). After 4 hours of incubation, the release of β-carotene in
the small intestine was significantly higher for the β-carotene-loaded NLC (233 μg/mL) compared to
the other formulations, indicating that NLC effectively released the β-carotene in the small intestine,
reducing degradation in the digestive tract. Furthermore, the bioavailability of β-carotene-loaded
NLC (60.7%) in the intestine exceeded the ones obtained from the emulsion (34.1%), the β-carotene-
tween 80 solution (23.4%), and β-carotene-phosphate buffered solution (8.7%). In terms of antioxidant
activity, β-carotene-loaded NLC exhibited moderate to strong antioxidant properties, with the 2,2′-
azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) and DPPH assay values of 91.47 ± 1.9 and
24.72 ± 0.38%, respectively. Additionally, the IC50 of the β-carotene-loaded NLC was 7.0 μg/mL, while
the pure β-carotene solution (standard) was 10.0 μg/mL, indicating enhanced antioxidant activity for
the encapsulated β-carotene. The study also evaluated the radical scavenging activity during the
digestive process and consistently demonstrated that β-carotene-loaded NLC exhibited higher
radical scavenging activity compared to the other tested systems. These results suggest that NLC may
be a promising vehicle for application in functional food and beverages.[34]

2.4. Astaxanthin
Geng et al. optimized and assessed the stability, skin retention ability, and permeability of
astaxanthin-loaded NLC. The optimization process involved adjusting different independent
variables, such as the solid lipid: liquid lipid ratio, total amount of lipids, astaxanthin concentration,
and type and amount of emulsifiers, while the dependent variables were particle size, PDI, and EE.
For the experiments, were prepared 21 formulations, and the optimized formulation showed stable
nanoparticles with a spherical surface, a particle size of 67.4 ± 2.1 nm, PDI of 0.26 and EE of 94.3 ±
0.5%. This formulation was also non-irritating, homogeneous, and exhibited excellent stability. The
in vitro release studies indicated that the cumulative release rate of astaxanthin from the NLC was
83.0 ± 3.4% for 48 hours, while pure astaxanthin dissolved completely within 4 hours. Moreover, the
antioxidant and anti-linoleic lipid peroxidation activities, were effectively preserved following
encapsulation in the NLC. The results of the skin penetration studies indicated that the cumulative
permeability within 24 hours was 174.10 ± 4.38 μg/cm² and the retention 18.60 ± 1.62 μg/cm² for
astaxanthin-loaded NLC, while pure astaxanthin demonstrated permeability and retention of 295.20
± 6.04 μg/cm² and 8.00 ± 1.62 μg/cm², respectively. Although the encapsulation of astaxanthin showed
a disadvantageous reduction in skin permeation, the NLC formulation showed a sustained release
profile compared with the free astaxanthin, reducing the amount of free astaxanthin that can
permeate through the skin. However, the skin retention of astaxanthin was effectively improved by
the encapsulation in the NLC, maximizing the local astaxanthin concentration in the skin while
reducing its systemic delivery. These findings suggest that NLC has potential to serve as a carrier for
astaxanthin, offering enhanced stability and improved skin retention capabilities.[35] Another
study tested the ability of astaxanthin-loaded NLC to reduce skin damage caused by radiotherapy.
In the experiments, were tested the effects of the formulation on human fibroblasts and in mice after
exposure to X-irradiation. The results showed that the astaxanthin-loaded NLC had particle size of
114.4 nm, ZP of −34.1 mV, and EE of 85.67%. Furthermore, astaxanthin-loaded NLC (0.25 μg/mL)
successfully reduced reactive oxygen species (ROS) production by 81.6%, decreased DNA damage
by 41.6%, and lowered cell death by 62.69%, compared to the control. In the in vivo experiments, all
six mice treated with astaxanthin-loaded NLC were protected from acute skin damage after nine days
of X-irradiation. In contrast, 5 out of 6 untreated mice exhibited grade-1 skin damage. Furthermore,
after 28 days of treatment, histological images indicated significant skin recovery with minimal
differences in collagen fibers and sebaceous glands compared to normal skin.[36] Other researches
have suggested that astaxanthin-loaded NLC could be employed in the production of food
supplements.[37] For example, researchers encapsulated astaxanthin in NLC and analyzed its
behavior during in vitro digestion. The particle size was 145.3 nm, the PDI was 0.468 ± 0.036, and the
ZP was -30.8 ± 0.3 mV. The EE was 94.8 ± 1.0%, and a long-term stability study revealed that around
75% of astaxanthin remained encapsulated, after 28 days of storage at 25ºC. In addition, the
antioxidant activity test demonstrated that the astaxanthin retained its biological activity after
Preprints.org (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 October 2024 doi:10.20944/preprints202410.1622.v1

10

encapsulation in the NLC. The in vitro release study showed that free astaxanthin was rapidly
released in the initial 6 hours, reaching approximately 90% after 12 hours, while encapsulated
astaxanthin exhibited a more sustained release profile, with 88% released in 24 hours. The results of
the formulation's digestion test indicated that the particle size and PDI remained stable during oral
and stomach digestion. However, during intestine digestion, the particle size increased significantly
(p < 0.05) to 227.6 ± 1.8 nm. This change was attributed to the presence of anionic components in the
micelle mixture, such as bile salts, phospholipids, and free fatty acids. Additionally, the digestion
process in the intestine initially occurred rapidly but then slowed down. The researchers concluded
that astaxanthin was trapped in the inner oil phase and suggested that the lipid matrix might
contribute to increased stability. These results suggest that NLC can be a promising delivery system
for astaxanthin, offering enhanced stability and prolonged release characteristics.[37]
Recent researches have suggested that encapsulating astaxanthin in NLC or SLN can enhance
the treatment of neurodegenerative diseases through the nose-to-brain route. For instance,
researchers conducted comparative in vitro experiments to evaluate the compatibility of astaxanthin-
loaded NLC and astaxanthin-loaded SLN with nasal and neuronal cells. They also assessed their
antioxidant activity (neuroprotective effect) and the cellular uptake of astaxanthin. The results
revealed that astaxanthin-loaded SLN particle size of 106.967 ± 2.515 nm, PDI of 0.220 ± 0.017, ZP of
−24.133 ± 0.379 mV, and EE of 99.99 ± 0.00%; while the astaxanthin-loaded NLC exhibited particle
size of 117.300 ± 2.163 nm, PDI of 0.222 ± 0.016, ZP of 23.267 ± 0.451 mV, and EE of 99.61 ± 0.04%.
Additionally, both astaxanthin-loaded NLC and astaxanthin-loaded SLN were found to be safe for
nasal and neuronal cells at concentrations up to 100 μg/mL. Regarding the neuroprotective effects,
both formulations exhibited ability to inhibit neurodegenerative pathways, such as oxidative stress.
Notably, the astaxanthin-loaded NLC demonstrated superior neuroprotective effects against
cytotoxicity induced by aggressors in comparison to the astaxanthin-loaded SLN.[39] In addition, in
the nose-to-brain route, a different study involving astaxanthin-loaded NLC was carried out to test
the in vivo effectiveness of this approach in slowing the progression of Alzheimer's disease. The
optimized astaxanthin-loaded NLC had particle size of 142.8 ± 5.02 nm, PDI of 0.247 ± 0.016, ZP of -
32.2 ± 7.88 mV, and EE of 94.1 ± 2.46%, and remained stable at 4-8 ± 2°C for six months. When
administered to rats with Alzheimer's disease-like symptoms, the astaxanthin-loaded NLC led to a
significant decrease in oxidative stress, amyloidogenic pathway, neuroinflammation, and apoptosis,
while also showing improvement in cholinergic neurotransmission compared to a free astaxanthin
solution.[38]

2.5. Lycopene, Fucoxanthin and Zeaxanthin

Okonogi et al. developed lycopene-loaded NLC for skin use, which had particle size of 166 ± 4
nm, PDI of 0.15 ± 0.05, ZP of -74.6 ± 2.0 mV and EE of 100 ± 0%. The in vitro release studies indicated
a biphasic profile with faster release in the first 6 hours followed by sustained release over the
following 18 hours. The in vitro occlusion test revealed increased occlusive properties with higher
lycopene loading in the NLC. Additionally, lycopene-loaded NLC exhibited higher antioxidant
capacity (36.6 ± 0.4 mM/mg) compared to the placebo NLC (26.6 ± 0.1 mM/mg). The IC50 obtained by
the DPPH assay was 14.1 ± 0.6 mg/mL for the lycopene-loaded NLC, and was 17.7 ± 0.4 mg/mL for
the placebo NLC. Physical stability studies showed that the particle size, PDI, and ZP of lycopene-
loaded NLC remained stable over 120 days, when stored at different temperatures (4, 30, and 40ºC).
Chemical stability data suggested that encapsulation in NLC improved the stability of lycopene,
particularly at lower temperatures (4ºC), which was demonstrated by the delay in lycopene
degradation (0.4 μg/mL/day).[40]
Two separate studies investigated the potential use of fucoxanthin encapsulated in SLN and
NLC for cosmetic applications. Cordenonsi et al. investigated the potential of fucoxanthin-loaded
NLC to prevent skin hyperproliferative diseases, particularly psoriasis. The developed fucoxanthin-
loaded NLC had a particle size of 427.3 ± 5.7 nm, PDI of 0.309 ± 0.11, ZP of 21.21 ± 1.23 mV and EE of
90.12 ± 2.51%. In vitro experiments on fibroblast cultures showed that up to a concentration of 5 mM
fucoxanthin there was no reduction in cell viability. Additionally, fucoxanthin-loaded NLC
Preprints.org (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 October 2024 doi:10.20944/preprints202410.1622.v1

11

decreased the expression of psoriatic markers by approximately 40%, suggesting its potential in
managing skin hyperproliferation and inflammation.[41] In the other study, Lee et al. assessed the
efficacy of fucoxanthin-loaded SLN to increase the effectiveness of sun protection. The results showed
that fucoxanthin-loaded SLN had particle size of 168 nm and PDI of 0.162, and could effectively
transport this active ingredient. In addition, the sun protection factor (SPF) of the fucoxanthin-loaded
SLN was significantly higher (1.85 times) than that of the other formulations tested (3 different
chemical sunscreens), demonstrating a remarkable sun protection enhancing effect.[42]
The only study found on zeaxanthin involved optimizing zeaxanthin-loaded SLN and
zeaxanthin-loaded NLC, were the respective particle size were 179.16 ± 0.94 nm and 130.16 ± 1.58 nm;
the PDI were 0.34 ± 0.01 and 0.30 ± 0.01; the ZP were -19.44 ± 1.19 mV and -21.49 ± 1.13 mV; and the
EE were 81.14 ± 3.06% and 90.43 ± 2.85%.The researchers suggested that both SLN and NLC could
have a wide range of applications, particularly as carriers for bioactive compounds in nutraceutical
beverages.[56]

2.6. Vitamin A
The first documented studies of vitamin A-loaded SLN date back to the early 2000s. Jenning et
al. developed vitamin A-loaded SLN and tested its efficacy in permeating porcine skin, comparing it
to a vitamin A nanoemulsion. The results revealed that SLN significantly enhanced the stability of
vitamin A compared to the nanoemulsion. The vitamin A-loaded SLN had a particle size of 224 nm
and a PDI of 0.205. Six hours after application, a substantial concentration of vitamin A
(approximately 3400 ng) was detected in the stratum corneum and the upper epidermis. In contrast,
the vitamin A nanoemulsion only transported 2500 ng to the upper skin layers (p < 0.05). Surprisingly,
after 24 hours, a change in the distribution pattern was observed. The concentration of vitamin A in
the upper epidermis decreased significantly to 900 ng (p < 0.05), while the concentration in the deeper
skin layers increased from 0 to 250 ng (p < 0.05). In contrast, the distribution pattern of the vitamin A
nanoemulsion did not change.[43] In another study, Pople et al. developed vitamin A-loaded SLN
with a particle size of 350 nm. The in vitro release studies showed that the vitamin A-loaded SLN had
a prolonged release of vitamin A for up to 24 hours, with 54.38% of the compound released, compared
to a 70% released observed with a vitamin A hydrogel. This extended release was attributed to the
compound being embedded in the solid lipid core. In in vitro penetration studies, after 24 hours, the
vitamin A concentration in the skin was almost 2 times higher with the vitamin A-loaded SLN
formulation compared to the one obtained with the vitamin A hydrogel. Only 1.2 % of the compound
was detected in the receptor compartment of the vitamin A-loaded SLN, while almost 10 times more
was detected in the vitamin A hydrogel, resulting in a significantly higher amount of unabsorbed
compound (around 72 %) compared to the vitamin A-loaded SLN (around 67 %). The skin hydration
studies in albino rats showed that the application of the conventional vitamin A hydrogel resulted in
a slight change in the thickness of the stratum corneum, while the application of the vitamin A-loaded
SLN led to a substantial increase in the thickness of the stratum corneum: 3-fold compared to the
hydrogel and 3.5-fold compared to the untreated skin. Additionally, the developed vitamin A-loaded
SLN showed a primary irritation index of 0.00, with no observed erythema or edema.[44]
The potential use of vitamin A-loaded SLN and vitamin A-loaded NLC in the food industry has
recently been investigated. The study focused on ensuring the stability and oral bioavailability of
these nanoparticles under food processing conditions. Six formulations were developed for the
experiments, from which two were selected for further investigation. The particle size, PDI, ZP and
EE for the vitamin A-loaded SLN were 223 ± 10 nm, 0.171 ± 0.008, -25 ± 1 mV and 97 ± 3%, respectively.
For vitamin A-loaded NLC, the corresponding values were 228 ± 7 nm, 0.146 ± 0.007, -22 ± 1 mV and
90 ± 1%. The results of the stability tests showed that these nanoparticles remained stable for one
month after storage at room temperature (25ºC). Furthermore, exposure to typical food processing
temperatures (60 and 70°C) did not significantly change the nanoparticle properties, although these
temperatures being above the melting point of the solid lipid used in the nanoparticles (43°C). The
nanoparticles were also tested in different media, including phosphate buffer at pH 5, highly
concentrated sucrose solution, and high ionic strength sodium chloride solution. Both the vitamin A-
Preprints.org (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 October 2024 doi:10.20944/preprints202410.1622.v1

12

loaded SLN and vitamin A-loaded NLC showed stability in all the tested media, with variations of <
10% compared to fresh formulations not exposed to the various media. Afterwards, to simulate
gastric conditions, the nanoparticles were subjected to a simulated gastric environment containing
an acidic pH, salts, and gastric enzymes.
Despite an increase of 0.03 in the PDI after two hours, the size of NLCs remained roughly the
same. A similar situation was observed for SLNs. Furthermore, after two hours in a simulated gastric
environment, approximately 80% of the encapsulated vitamin A remained intact in the SLN and
NLC, suggesting their potential to deliver the compound to the intestine where it can be absorbed.[45]

2.7. Vitamin D, E and K

The potential of using NLC to improve the effectiveness of vitamin D3 in fighting breast cancer
cells has been investigated. The developed vitamin D3-loaded NLC showed that a particle size of 87
± 5 nm, PDI of 0.24, and ZP of -12.2 ± 4.86 mV. The 3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide (MTT) assay showed that vitamin D3-loaded NLC was more
successful in inhibiting cancer cell proliferation compared to free vitamin D3 (p < 0.05), reducing cell
proliferation from 49 ± 7.2% to 37 ± 5.1%, respectively. Furthermore, vitamin D3-loaded NLC
increased the percentage of cells in the apoptotic phase to 40 ± 3.45% (p < 0.05). These findings suggest
that vitamin D3-loaded NLC can improve the efficacy of chemotherapeutics in breast cancer
patients.[46] Another study suggested using oral vitamin D3-loaded NLC to improve the
management of inflammatory bowel disease. The vitamin D3-loaded NLC had a particle size of 110
± 4 nm, PDI of 0.23 ± 0.01 and ZP of -17.10 ± 0.30 mV. When vitamin D3-loaded NLC was orally
administered to mice, the concentration of vitamin D3 in the colon was observed to be three times
higher than the basal level, persisting for at least 12 hours (p < 0.01). Subsequently, the researchers
assessed the effects of vitamin D3-loaded NLC on intestinal inflammation. The results demonstrated
that although the symptoms worsened in mice treated with free vitamin D3 and vitamin D3-loaded
NLC, the group tested with the NLC experienced a progressive mitigation of clinical symptoms from
day 3, and suppressed the decrease in body weight from day 6. Additionally, the histological
examination of colonic tissue showed significantly reduced inflammatory manifestations, immune
cell infiltration, and crypt destruction in the group treated with vitamin D3-loaded NLC (p < 0.01).[47]
Eiras et al. developed a vitamin E-loaded NLC and assessed its potential for skin application.
The characterization of the NLC loaded with vitamin E showed that the particles had a consistent
size in the nanometer range, with 90% having a size of less than 328 nm and 50% having a size of less
than 105 nm, even after 7 months of storage. The results of in vitro studies indicated that the vitamin
E-loaded NLC is biocompatible and non-irritant (with a score of 0.00), being suitable for skin
application. From these findings, the researchers proposed using vitamin E-loaded NLC in cosmetic
and dermatological formulations to improve skin hydration.[48] Latter, the same researchers
conducted a more comprehensive study with this formulation, where they found no significant
differences in particle size after incorporating vitamin E-loaded NLC into a hydrogel (D90= 386 ± 0.00
nm vs. D90= 397 ± 0.021 nm). The biocompatibility studies were assessed by the MTT assay, where it
was observed that the vitamin E-loaded NLC was more cytotoxic to human keratinocytes before
incorporation in the hydrogel (IC50 = 14.38 μg/mL vs. IC50 = 28.74 μg/mL, p < 0.001). In vitro and in vivo
tests, revealed that vitamin E-loaded NLC demonstrated superior occlusive properties (80% vs. 67%)
and significantly reduced the skin transepidermal water loss (TEWL) compared to a vitamin E
nanoemulsion (p < 0.05). In this study, the researchers demonstrated the safety and hydration
potential of the hydrogel containing vitamin E-loaded NLC for skin application. However, it was
emphasized the need for more in vivo experiments over extended periods and involving more
volunteers to confirm these evidences.[49] In another study, the effectiveness of vitamin E-loaded
NLC was examined for its moisturizing and anti-aging properties. The optimized vitamin E-loaded
NLC had a particle size of 82 nm, a PDI of 0.261, a ZP of -28.6 mV, and an EE of 95.83 ± 0.02%. The
stability study revelated that the nanoparticles maintained their spherical shape and physical stability
for 12 weeks, after storage at room temperature. The release profile indicated that 30% of the vitamin
E was released within the first 5 hours, with 70% released after 24 hours. The vitamin E-loaded NLC
Preprints.org (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 October 2024 doi:10.20944/preprints202410.1622.v1

13

was incorporated into a hydrogel base and in vivo tests were performed on 13 human volunteers over
12 weeks to assess skin moisture content and mechanical properties. In the skin irritation test, all
volunteers showed no signs of erythema after 48 hours of exposure to the hydrogel containing the
vitamin E-loaded NLC. However, 3 out of 13 volunteers experienced mild erythema when exposed
to the vitamin E hydrogel alone. This suggests that the free form of vitamin E can be irritating to the
skin, but the NLC provides a protective effect against this irritation. Additionally, throughout the 12-
week study period the hydrogel containing the vitamin E-loaded NLC enhanced skin elasticity
capacity (p = 0.0319) and consistently increased skin moisture levels by 80%, while a vitamin E
hydrogel only resulted in a 20% increase in moisture levels (p < 0.01).[50] In a different approach, the
researchers evaluated the effectiveness of encapsulating vitamin E in SLN to reduce the negative
effects of anemia treatment. The characterization of the vitamin E-loaded SLN revealed a particle size
of 228.2 ± 3.5 nm, a PDI of 0.34 ± 0.02, a ZP of -8.92 ± 2.2 mV and an EE of 99.9 ± 0.1%. The in vitro
release studies revealed that approximately 65% of the encapsulated vitamin E was released after 24
hours in simulated gastrointestinal media at 37 °C. Furthermore, the vitamin E-loaded SLN
demonstrated good hemocompatibility at various concentrations. After 3 hours of incubation, there
was minimal hemolysis (less than 0.3%). Even after 24 and 48 hours, the level of hemolysis remained
low, with less than 3.0% at the highest SLN concentration. It's important to note that biomaterials
causing hemolysis of less than 5% are generally considered safe for human use, according to ISO/TR
7406. These results indicate their potential for clinical applications. Notably, the vitamin E-loaded
SLN significantly boosted lymphocyte cell proliferation by approximately 150% and decreased DNA
damage caused by the iron treatment.[51]
Regarding vitamin K, only one significant study involving the encapsulation of vitamin K1 in
SLN for oral delivery was found. In the experiments, seventeen different formulations were prepared
and the most effective one was chosen for further tests. The particle size, PDI, ZP and EE for the
vitamin K-loaded SLN were 132 nm, 0.17 ± 0.02, and -26.83 ± 2.83 mV, 98%, respectively. This
formulation was shown to be stable in a 54-hour in vitro release study in simulated gastric and
intestinal media and after 4 months storage at 25°C. [52]

2.8. Chitosan
Almeida et al. aimed to evaluate the efficacy of chloroaluminium phthalocyanine-loaded NLC,
optimized and coated with chitosan, in photodynamic therapy of skin cancer. Chloroaluminium
phthalocyanine-loaded NLC coated with chitosan showed a particle size of 231.5 ± 5.8 nm, a PDI of
0.18 ± 0.01, a ZP of +19.96 mV and an EE of 96%. It is important to highlight that the chitosan coating
resulted in larger, but equally viable, nanoparticles. Ex vivo studies showed that the phthalocyanine-
loaded NLC coated with chitosan significantly retained the compound in the skin after 2 h (5.8 ng)
and 4 h (581 ng), with no detection in the bloodstream, indicating limited systemic exposure and no
potential adverse events in patients. The biocompatibility test performed on L929 fibroblasts showed
that the phthalocyanine-loaded NLC coated with chitosan did not induce cytotoxicity at any of the
concentrations tested, indicating that the chitosan coating did not affect the biocompatibility of the
NLC. It was also observed that the phthalocyanine-loaded NLC coated with chitosan were localized
around the cellular nucleus. The photodynamic therapy tests performed on BF16-F10 melanoma cells
showed that phthalocyanine-loaded NLC coated with chitosan did not have toxic effects when not
exposed to irradiation. However, after irradiation there was a 50% reduction in cell viability (p <
0.001). These results highlight that the chitosan coating improved stability, biocompatibility, and
facilitated drug passage through the skin.[53]

2.9. Alginate

Costa-Fernandez et al. developed an NLC co-encapsulated with vitamin E and quercetin and
coated with alginate to investigate its potential to promote wound healing and to evaluate the
influence of the alginate coating in enhancing the penetration of the encapsulated compounds into
the skin damaged by an incision. The results showed that the alginate-coated NLC co-encapsulated
with vitamin E and quercetin had a particle size of 321.2 ± 18.3 nm, a PDI of 0.23 ± 0.02 a ZP of -16.0
Preprints.org (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 October 2024 doi:10.20944/preprints202410.1622.v1

14

± 3.0 mV and an EE of 85% for quercetin and 92% for vitamin E. The irritation potential of the
developed alginate-coated NLC was assessed by the Hen's Egg Test - chorioallantoic membrane,
showing that they did not induce bleeding, lysis or coagulation. Regarding the in vitro release, it was
observed 44.2% of quercetin released and 32.3% of vitamin E released after 16 h. Furthermore, the
release of vitamin E from NLC increased 1.9-fold and the release of quercetin from NLC increased
2.3-fold compared to intact skin. The TEWL was also reduced when using alginate-coated NLC co-
encapsulated with vitamin E and quercetin. The results highlight the advantages of using
polysaccharides, such as alginate, as bioadhesive polymers to promote the penetration of compounds
into the upper layers of the skin.[54]

2.10. Gelatin
Gelatine, a natural biopolymer (i.e. a protein composed of long chains of amino acids), is widely
used in the food industry because of its advantages such as non-toxicity, low cost, availability,
biocompatibility, and biodegradability. Researches has shown that gelatin can stabilize nanocarriers
due to its amine and carboxylic groups. Malekmohammadi et al. conducted a study aiming to
synthesize gelatin-coated NLC to encapsulate sage extract for inhibiting microbial growth and lipid
oxidation in beef burgers. The optimized sage extract-loaded NLC coated with gelatin had a particle
size of 100.4 nm, PDI of 0.36, ZP of −18.4 mV, and EE of 80%. The results of the DPPH assay showed
that the sage extract-loaded NLC coated with gelatin exhibited significantly higher antioxidant
activity than the free extract, after 30 days of storage at 25ºC (p < 0.05). It also observed a higher
inhibitory effect against E. coli compared to the free extract in the minimum inhibitory concentration
(0.1 ± 0.00 vs. 0.2 ± 0.00 mg/mL) and the minimum bactericidal concentration (0.1 ± 0.00 vs. 0.3 ± 0.00
mg/mL) tests. Furthermore, incorporating the formulation into beef burgers increased their oxidation
stability during 90 days of storage, at 4 and −18 °C (p < 0.05). The sage extract-loaded NLC coated
with gelatin also effectively decreased the total counts of various bacteria, yeasts, and molds in
treated beef burger samples during storage in comparison to the controls (all p < 0.05). The sensory
tests showed no significant differences in the color, odor, texture and flavor attributes of the beef
burger samples immediately after preparation. However, over time, the treated samples showed
greater acceptability. These improved sensory properties were attributed to reduced proteolytic and
lipolytic reactions, as well as reduced microbial activities. Overall, the study suggests that sage
extract-loaded NLC coated with gelatin can be an effective preservative for extending the shelf life of
beef burgers.[55]

3. Regulatory and Safety Concerns of Lipid Nanoparticles for Healthcare Applications

3.1. Cosmetics
Despite the regulatory frameworks governing the global market for nanocosmetics, the
recognition of nanomaterials as cosmetic ingredients remains inconsistent across jurisdictions.[57]
Consequently, each country adheres to its legal system. Given that the European Union (EU) and the
United States of America (USA) represent the two most significant markets for cosmetics products,
their respective regulatory frameworks are of considerable importance. However, there are notable
discrepancies between the two. Prior to 2023, the USA did not require cosmetic product registration,
while the EU has mandated registration since 2013, especially for products containing nanoparticles.
Furthermore, a notification to the European Commission (EC), including information on the
identification, specifications, toxicological profile, and safety of the nanomaterials, is required. In
cases of uncertainty regarding the safety of a nanomaterial, the EC can request an opinion from the
Scientific Committee on Consumer Safety (SCCS).[58] Under the stipulations set in the EC Regulation
1223/2009, the term "nanomaterial" is defined to regulate cosmetics products as a deliberately
insoluble or bio-persistent manufactured material that has external dimensions (one or more) or an
internal structure within the range of 1 to 100 nanometers. On the other hand, in the USA, the Food
and Drug Administration (FDA) oversees the use of nanomaterials in cosmetics through the Federal
Food, Drug, and Cosmetic Act (FFDCA). However, the FDA does not have a legal definition for
Preprints.org (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 October 2024 doi:10.20944/preprints202410.1622.v1

15

nanotechnology, does not approve the ingredients in cosmetic formulations, and does not require
manufacturers to disclose the presence of nanomaterials in their products. The FDA has thus far
refrained from making a definitive determination regarding the inherent safety or potential risks
associated with nanotechnology.[59] In consequence, the FDA has created the National
Nanotechnology Initiative (NNI) and the Nanotechnology Task Force (NTF) intending to assess the
restrictions required for nanotechnology products. These entities have published two documents
addressing the safety issues of nanotechnology and cosmetics, which merely make
recommendations. The first document is concerned with the determination of a material's
classification as a nanomaterial based on the size of the particles and their properties/phenomena. In
particular, it considers whether the material or final product is: a) intentionally designed to have at
least one external dimension, internal dimension, or surface structure within the nanoscale range
(approximately 1 nm to 100 nm); b) meant to exhibit properties or phenomena, including physical,
chemical, or biological effects, attributed to its size, even if these dimensions extend beyond the
nanoscale range to one micrometer (1000 nm). It is important to highlight that the properties of
nanomaterials relevant to safety, effectiveness, performance, quality evaluation, public health impact,
and product regulatory status can be linked to materials with one or more dimensions larger than the
1–100 nm range. In a succeeding document, the FDA advises a thorough assessment of safety by
characterizing the nanomaterial itself and examining a wide range of chemical and physical
properties. This involves evaluating the toxicity, absorption, distribution, metabolism, and excretion
of the particles.[57,60]
The scientific community has been debating whether the use of insoluble nanoparticles in
cosmetics poses a health risk. The results so far have been inconclusive due to inconsistent findings
and a lack of long-term toxicological studies. Safety evidence originates mainly from the EU, which
has strict regulations.[60] When it comes to using SLN and NLC in cosmetics, these can be classified
as nanomaterials according to EU standards, as they consist of water-insoluble materials, such as
solid and liquid lipids. However, these lipids are similar to the body's natural lipids. They can readily
adhere to and interact with the outer layer of the skin, causing lipid rearrangement and allowing the
encapsulated compounds to penetrate deeper layers of the skin.
Furthermore, the nanoscale dimensions of the particles facilitate enhanced adhesion and surface
contact area, which in turn improves the permeation of the compound through the skin.[17]
Accordingly, they are regarded as soluble substances.[60] Moreover, the utilization of SLN and NLC
in topical cosmetics has been documented to diminish the probability of these carriers causing
systemic toxicity.[29] In light, SLN and NLC in cosmetic products are not subject to any objections or
safety concerns, as stipulated by the pertinent legislation.

3.2. Food Supplements

The regulation No 2015/2283 of the EC defines engineered nanomaterials in food as novel foods,
categorizing them as intentionally produced materials with dimensions of approximately 100 nm or
less. These materials can have discrete functional parts at the surface or internally, as well as
structures, aggregates, or agglomerates, which may maintain nanoscale-specific properties despite
having a size above 100 nm. Such properties may be related to specific physicochemical properties
that differ from those of the non-nano form of the same material and/or to the large specific surface
area of the materials considered. Nevertheless, the EU legislation applicable to novel food is the same
as to all food (Regulation EC No 178/2002).[61] Concerning this legislation, certain safety stipulations
give rise to uncertainty, particularly the potential adverse effects of the novel food on the health of
both the current and future generations.[62] Regarding long-term effects, there is a gap in data to
substantiate the safety of nanoparticles. However, the European Food Safety Authority (EFSA) has
issued an exceptional document that provides an overview of the risk assessment of nanomaterials
in food and the requisite information.[63] The document elucidated that lipid nanoparticles can
facilitate the delivery of select food components, particularly those exhibiting pronounced
lipophilicity. Moreover, the components of the nanoparticle can be derived from naturally occurring
body lipids or approved food additives, such as emulsifiers. The primary safety concerns pertain to
Preprints.org (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 October 2024 doi:10.20944/preprints202410.1622.v1

16

the extent of degradation of the encapsulation materials within the gastrointestinal tract. This
encompasses not only the active ingredient itself but also the encapsulating material and the entire
encapsulate/nanocarrier. In this regard, it has been proposed that specific adaptations in hazard
characterization are required, including the assessment of the quantity of the encapsulated
compound and the amount present in its free form in the food. Moreover, it may be advisable to
examine the pertinent chemical constituents of a nanocarrier system and present evidence on how
intestinal cells absorb and transport them.[64]
In the USA, the FDA adheres to the same stance as the EFSA. They monitor the safety and
effectiveness of nanotechnology products. As well as regulate these products within its current
regulatory framework, customized to the specific standards for each product category under its
authority. As a result, the industry is committed to ensuring compliance with all applicable legal
requirements and is encouraged to collaborate with the FDA to address any concerns regarding the
safety or regulatory status of these products.[59]
The safety of SLN and NLC in food supplements has been reported. Once ingested, these
nanoparticles undergo the same physiological processes as the lipids present in food. The process
includes digestion in the stomach, absorption primarily in the small intestine, and systemic blood
uptake. In the small intestine, SLN and NLC can be broken down by lipase enzymes, releasing and
facilitating the absorption of the compounds. Additionally, lipid nanoparticles have adhesive
properties, allowing them to adhere to the gut wall, specifically the enterocyte surface, leading to
prompt absorption of the compounds within the enterocytes.
Additionally, oral lipid nanoparticles are generally larger than 100 nm and biodegradable,
indicating that their cellular uptake is not expected. Therefore, it is reasonable to conclude that no
significant toxicological concerns are anticipated.[65,66]

4. Conclusions
In recent years, concerns about sustainability and well-being have motivated research into the
discovery of bioactive compounds from natural sources that are safe for human consumption. In this
context, the potential health benefits of marine bioactive compounds have been described by several
researchers. However, most of these molecules have stability problems and low water solubility, so
the use of lipid nanoparticles such as SLN and NLC has proved effective in overcoming these
problems. Indeed, the data presented in this review work demonstrates the potential of these
nanoparticles to improve the use of bioactive marine compounds in healthcare applications,
particularly in cosmetics and food supplements.
Noteworthy, most of the current studies are based on in vitro experiments and there is a lack of
information on regulatory and safety standards for human use. It is therefore important to give
priority in the future to:
- Standardization of clinical trial protocols to allow comparisons between different studies.
- Carrying out in vivo studies to obtain more information on the absorption, distribution and
excretion of bioactive compounds and their nanocarriers.
- Conducting additional tests in human volunteers to confirm that the results observed in animal
studies apply to humans.
- Sharing "bad results" to avoid redundant efforts, promote transparency and accelerate
collective learning.
Academia and industry must work together to overcome technological and financial constraints.
This partnership is essential to drive innovation, bridge the gap between theory and practice and
ensure that research addresses real-world challenges. It is also essential to ensure that regulatory
standards are kept up to date with the latest scientific advances to ensure safety and progress.

Acknowledgments: This work was supported by the Fundação para a Ciência e a Tecnologia - FCT
(2023.02170.BDANA) and by the Applied Molecular Biosciences Unit - UCIBIO, which is financed by national
funds from FCT (UIDP/04378/2020 and UIDB/04378/2020).
Preprints.org (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 October 2024 doi:10.20944/preprints202410.1622.v1

17

References
1. Favas, R.; Morone, J.; Martins, R.; Vasconcelos, V.; Lopes, G., Cyanobacteria and microalgae bioactive
compounds in skin-ageing: potential to restore extracellular matrix filling and overcome
hyperpigmentation. Journal of Enzyme Inhibition and Medicinal Chemistry 2021, 36 (1), 1829–1838.
2. Augusto, A.; Lemos, M. F. L.; Silva, S. F. J., Exploring Marine-Based Food Production: The Challenges for
a Sustainable and Fast Biotechnology-Based Development. Applied Sciences 2024, 14 (18).
3. Pateiro, M.; Domínguez, R.; Munekata, P. E. S.; Barba, F. J.; Lorenzo, J. M., Lipids and fatty acids.
Innovative Thermal and Non-Thermal Processing, Bioaccessibility and Bioavailability of Nutrients and
Bioactive Compounds 2019, 107–137.
4. Burdge, G. C.; Calder, P. C., Introduction to Fatty Acids and Lipids. Intravenous Lipid Emulsions 2014, 1–16.
5. Roy, V. C.; Islam, M. R.; Sadia, S.; Yeasmin, M.; Park, J.-S.; Lee, H.-J.; Chun, B.-S. Trash to Treasure:
An Up-to-Date Understanding of the Valorization of Seafood By-Products, Targeting the Major Bioactive
Compounds Marine Drugs [Online], 2023.
6. Misawa, N., Comprehensive Natural Products II. In Chemistry, Molecular Sciences and Chemical Engineering,
Elsevier, Ed. Elsevier BV: Elsevier, 2010; Vol. 1, pp 733-753.
7. Chuyen, H. V.; Eun, J.-B., Marine carotenoids: Bioactivities and potential benefits to human health. Critical
Reviews in Food Science and Nutrition 2015, 57 (12), 2600–2610.
8. Carpenter, K.; Baigent, M. J. Vitamin. https://www.britannica.com/science/vitamin (accessed January, 23).
9. Rucker, R. B.; Morris, J. G., The Vitamins. Clinical Biochemistry of Domestic Animals 1997, 703–739.
10. Thawabteh, A.; Swaileh, Z.; Ammar, M.; Jaghama, W.; Yousef, M.; Karaman, R.; Bufo, S.; Scrano,
L., Antifungal and Antibacterial Activities of Isolated Marine Compounds. Toxins 2023, 15, 1-22.
11. Venkatesan, J.; Anil, S.; Kim, S.-K.; Shim, M., Marine Fish Proteins and Peptides for Cosmeceuticals: A
Review. Marine Drugs 2017, 15, 143.
12. Hu, D.; Jin, Y.; Hou, X.; Zhu, Y.; Chen, D.; Tai, J.; Chen, Q.; Shi, C.; Ye, J.; Wu, M.; Zhang, H.;
Lu, Y. Application of Marine Natural Products against Alzheimer&rsquo;s Disease: Past, Present and
Future Marine Drugs [Online], 2023.
13. Fonseca, S.; Amaral, M. N.; Reis, C. P.; Custódio, L. Marine Natural Products as Innovative Cosmetic
Ingredients Marine Drugs [Online], 2023.
14. Almeida, H.; Amaral, M. H.; Lobão, P., Silva, A. C.; Loboa, J. M. S., Applications of Polymeric and Lipid
Nanoparticles in Ophthalmic Pharmaceutical Formulations: Present and Future Considerations. Journal of
Pharmacy & Pharmaceutical Sciences 2014, 17 (3), 278–293.
15. Seo, Y.; Lim, H.; Park, H.; Yu, J.; An, J.; Yoo, H. Y.; Lee, T., Recent Progress of Lipid Nanoparticles-
Based Lipophilic Drug Delivery: Focus on Surface Modifications. Pharmaceutics 2023, 15 (3).
16. González-Peña, M. A.; Ortega-Regules, A. E.; Anaya de Parrodi, C.; Lozada-Ramírez, J. D., Chemistry,
Occurrence, Properties, Applications, and Encapsulation of Carotenoids-A Review. . Plants (Basel,
Switzerland) 2023, 12 (2).
17. Garcês, A.; Amaral, M. H.; Sousa Lobo, J. M.; Silva, A. C., Formulations based on solid lipid
nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: A review. European Journal
of Pharmaceutical Sciences 2018, 112, 159–167.
18. Preeti; Sambhakar, S.; Saharan, R.; Narwal, S.; Malik, R.; Gahlot, V.; Mohan, S., Exploring LIPIDs
for their potential to improves bioavailability of lipophilic drugs candidates: A review. Saudi Pharmaceutical
Journal 2023, 31 (12).
19. Tenchov, R.; Bird, R.; Curtze, A. E.; Zhou, Q., Lipid Nanoparticles horizontal line From Liposomes to
mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano 2021, 15 (11),
16982-17015.
20. Mohammed, A. S. A.; Naveed, M.; Jost, N., Polysaccharides; Classification, Chemical Properties, and
Future Perspective Applications in Fields of Pharmacology and Biological Medicine (A Review of Current
Applications and Upcoming Potentialities). Journal of Polymers and the Environment 2021, 29 (8), 2359-2371.
21. Ju, H.; Yu, C.; Liu, W.; Li, H.-H.; Fu, Z.; Wu, Y.-C.; Gong, P.-X.; Li, H.-J., Polysaccharides from
marine resources exhibit great potential in the treatment of tumor: A review. Carbohydrate Polymer
Technologies and Applications 2023, 5, 100308.
22. Tan, K.; Lu, S.-Y.; Tan, K.; Ransangan, J.; Cai, X.; Cheong, K.-L., Bioactivity of polysaccharides
derived from bivalves. International Journal of Biological Macromolecules 2023, 250, 126096.
23. Liu, Q.; Hu, L.; Wang, C.; Cheng, M.; Liu, M.; Wang, L.; Pan, P.; Chen, J., Renewable marine
polysaccharides for microenvironment-responsive wound healing. International Journal of Biological
Macromolecules 2023, 225, 526-543.
24. Wang, Z.; Xu, Z.; Yang, X.; Li, M.; Yip, R. C. S.; Li, Y.; Chen, H., Current application and
modification strategy of marine polysaccharides in tissue regeneration: A review. Biomaterials Advances
2023, 154, 213580.
25. Sahraee, S.; Ghanbarzadeh, B.; Maryam mohammadi, P., A.; hoseini, M., Development of heat-stable
gelatin-coated nanostructured lipid carriers (NLC): Colloidal and stability properties. LWT 2022, 160.
Preprints.org (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 October 2024 doi:10.20944/preprints202410.1622.v1

18

26. Muller, R. H.; Radtke, M.; Wissing, S. A., Solid lipid nanoparticles (SLN) and nanostructured lipid carriers
(NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002, 54 Suppl 1, S131-55.
27. Muller, R. H.; Shegokar, R.; Keck, C. M., 20 years of lipid nanoparticles (SLN and NLC): present state of
development and industrial applications. Curr Drug Discov Technol 2011, 8 (3), 207-27.
28. Silva, A. C.; González-Mira, E.; García, M. L.; Egea, M. A.; Fonseca, J.; Silva, R.; Santos, D.; Souto,
E. B.; Ferreira, D., Preparation, characterization and biocompatibility studies on risperidone-loaded solid
lipid nanoparticles (SLN): High pressure homogenization versus ultrasound. Colloids and Surfaces B:
Biointerfaces 2011, 86 (1), 158–165.
29. Pardeike, J.; Hommoss, A.; H. Müller, R., Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical
dermal products. International Journal of Pharmaceutics 2009, 366 (1-2), 170-184.
30. Lima, S. G. M.; Freire, M. C. L. C.; Oliveira, V. d. S.; Solisio, C.; Converti, A.; de Lima, Á. A. N.,
Astaxanthin Delivery Systems for Skin Application: A Review. Marine Drugs 2021, 19.
31. Serini, S.; Cassano, R.; Corsetto, P. A.; Rizzo, A. M.; Calviello, G.; Trombino, S., Omega-3 PUFA
Loaded in Resveratrol-Based Solid Lipid Nanoparticles: Physicochemical Properties and Antineoplastic
Activities in Human Colorectal Cancer Cells In Vitro. International journal of molecular sciences 2018, 19 (2).
32. Li, Z.; Yin, Z.; Li, B.; He, J.; Liu, Y.; Zhang, N.; Li, X.; Cai, Q.; Meng, W., Docosahexaenoic Acid-
Loaded Nanostructured Lipid Carriers for the Treatment of Peri-Implantitis in Rats. International Journal of
Molecular Sciences 2023, 24 (3).
33. Maretti, E.; Leo, E.; Rustichelli, C.; Truzzi, E.; Siligardi, C.; Iannuccelli, V., In vivo β-carotene skin
permeation modulated by Nanostructured Lipid Carriers. International Journal of Pharmaceutics 2021, 597.
34. Rohmah, M.; Rahmadi, A.; Raharjo, S., Bioaccessibility and antioxidant activity of β-carotene loaded
nanostructured lipid carrier (NLC) from binary mixtures of palm stearin and palm olein. Heliyon 2022, 8
(2).
35. Geng, Q.; Zhao, Y.; Wang, L.; Xu, L.; Chen, X.; Han, J., Development and Evaluation of Astaxanthin
as Nanostructure Lipid Carriers in Topical Delivery. . AAPS PharmSciTech 2020, 21 (8).
36. Vu, N. B. D.; Pham, N. D.; Tran, T. N. M.; Pham, X. H.; Ngo, D. N.; Nguyen, M. H., Possibility of
nanostructured lipid carriers encapsulating astaxanthin from Haematococcus pluvialis to alleviate skin
injury in radiotherapy. I nternational Journal of Radiation Biology 2023, 1-11.
37. Mao , X.; Tian , Y.; Sun , R.; Wang , Q.; Huang, J.; Xia, Q., Stability study and in vitro evaluation
of astaxanthin nanostructured lipid carriers in food industry. Integrated Ferroelectrics 2019, 200 (1), 208-216.
38. Shehata , M.; Ismail, A.; Kamel, M., Nose to Brain Delivery of Astaxanthin–Loaded Nanostructured
Lipid Carriers in Rat Model of Alzheimer’s Disease: Preparation, in vitro and in vivo Evaluation.
International Journal of Nanomedicine 2023, 18, 1631-1658.
39. Torres, J.; Pereira, J. M.; Marques-Oliveira, R.; Costa, I.; Gil-Martins, E.; Silva, R.; Remião, F.;
Peixoto, A. F.; Sousa Lobo, J. M.; Silva, A. C., An In Vitro Evaluation of the Potential Neuroprotective
Effects of Intranasal Lipid Nanoparticles Containing Astaxanthin Obtained from Different Sources:
Comparative Studies. Pharmaceutics 2023, 15 (4).
40. Okonogi, S.; Riangjanapatee, P., Physicochemical characterization of lycopene-loaded nanostructured lipid
carrier formulations for topical administration. International Journal of Pharmaceutics 2015, 478 (2), 726–735.
41. Malgarim Cordenonsi, L.; Faccendini, A.; Catanzaro, M.; Bonferoni, M. C.; Rossi, S.; Malavasi, L.;
Raffin, R.; Schapoval, E.; Lanni, C.; Sandri, G.; Ferrari, F., The role of chitosan as coating material for
nanostructured lipid carriers for skin delivery of fucoxanthin. International Journal of Pharmaceutics 2019,
567.
42. Lee, Y.-J.; Nam, G.-W., Sunscreen Boosting Effect by Solid Lipid Nanoparticles-Loaded Fucoxanthin
Formulation. Cosmetics 2020, 7 (1).
43. Jenning, V.; Gysler, A.; Schäfer-Korting, M.; Gohla, S. H., Vitamin A loaded solid lipid nanoparticles for
topical use: occlusive properties and drug targeting to the upper skin. European journal of pharmaceutics and
biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 2000, 49 (3),
211–218.
44. Pople, P. V.; Singh, K. K., Development and evaluation of topical formulation containing solid lipid
nanoparticles of vitamin A. AAPS PharmSciTech 2006, 7 (91), E63-E69.
45. Resende, D.; Costa Lima, S. A.; Reis, S., Nanoencapsulation approaches for oral delivery of vitamin A.
Colloids and Surfaces B: Biointerfaces 2020, 193.
46. Sabzichi , M.; Mohammadian , J.; Mohammadi , M.; Jahanfar , F.; Movassagh Pour , A.;
Hamishehkar, H.; Ostad-Rahimi, A., Vitamin D-Loaded Nanostructured Lipid Carrier (NLC): A New
Strategy for Enhancing Efficacy of Doxorubicin in Breast Cancer Treatment. Nutrition and Cancer 2017, 69
(6), 840-848.
47. Zai, K.; Hirota, M.; Yamada, T.; Ishihara, N.; Mori, T.; Kishimura, A.; Suzuki, K.; Hase, K.;
Katayama, Y., Therapeutic effect of vitamin D3-containing nanostructured lipid carriers on inflammatory
bowel disease. Journal of Controlled Release 2018, 286, 94–102.
Preprints.org (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 October 2024 doi:10.20944/preprints202410.1622.v1

19

48. Eiras, F.; Amaral, M. H.; Silva, R.; Martins, E.; Lobo, J. M. S.; Silva, A. C., Characterization and
biocompatibility evaluation of cutaneous formulations containing lipid nanoparticles. Int J Pharm 2017, 519
(1-2), 373-380.
49. Vaz, S.; Silva, R.; Amaral, M. H.; Martins, E.; Sousa Lobo, J. M.; Silva, A. C., Evaluation of the
biocompatibility and skin hydration potential of vitamin E-loaded lipid nanosystems formulations: In vitro
and human in vivo studies. Colloids and Surfaces B: Biointerfaces 2019, 179, 242–249.
50. Ijaz, M.; Akhtar, N., Fatty acids based α-Tocopherol loaded nanostructured lipid carrier gel: In vitro and in
vivo evaluation for moisturizing and anti-aging effects. Journal of Cosmetic Dermatology 2020, 19 (11), 3067-
3076.
51. Gambaro, R. C.; Berti, I. R.; Cacicedo, M. L.; Gehring, S.; Alvarez, V. A.; Castro, G. R.; Seoane, A.;
Padula, G.; Islan, G. A., Colloidal delivery of vitamin E into solid lipid nanoparticles as a potential
complement for the adverse effects of anemia treatment. Chemistry and Physics of Lipids 2022, 249.
52. Liu, C.-H.; Wu, C.-T.; Fang, J.-Y., Characterization and formulation optimization of solid lipid
nanoparticles in vitamin K1 delivery. Drug Development and Industrial Pharmacy 2010, 36 (7), 751-761.
53. Almeida, E. D. P.; Santos Silva, L. A.; de Araujo, G. R. S.; Montalvao, M. M.; Matos, S. S.; da Cunha
Gonsalves, J. K. M.; de Souza Nunes, R.; de Meneses, C. T.; Oliveira Araujo, R. G.; Sarmento, V. H.
V.; De Lucca, W. J.; Correa, C. B.; Rodrigues, J. J. J.; Lira, A. A. M., Chitosan-functionalized
nanostructured lipid carriers containing chloroaluminum phthalocyanine for photodynamic therapy of
skin cancer. Eur J Pharm Biopharm 2022, 179, 221-231.
54. Costa-Fernandez, S.; Matos, J. K. R.; Scheunemann, G. S.; Salata, G. C.; Chorilli, M.; Watanabe, I. S.;
de Araujo, G. L. B.; Santos, M. F.; Ishida, K.; Lopes, L. B., Nanostructured lipid carriers containing
chitosan or sodium alginate for co-encapsulation of antioxidants and an antimicrobial agent for potential
application in wound healing. Int J Biol Macromol 2021, 183, 668-680.
55. Malekmohammadi, M.; Ghanbarzadeh, B.; Hanifian, S.; Samadi Kafil, H.; Gharekhani, M.; Falcone,
P. M., The Gelatin-Coated Nanostructured Lipid Carrier (NLC) Containing Salvia officinalis Extract:
Optimization by Combined D-Optimal Design and Its Application to Improve the Quality Parameters of
Beef Burger. Foods 2023, 12 (20).
56. Osanlou, R.; Emtyazjoo, M.; Banaei, A.; Hesarinejad, M. A.; Ashrafi, F., Preparation of solid lipid
nanoparticles and nanostructured lipid carriers containing zeaxanthin and evaluation of physicochemical
properties. Colloids and Surfaces A: Physicochemical and Engineering Aspects 2022, 641.
57. Oliveira, C.; Coelho, C.; Teixeira, J. A.; Ferreira-Santos, P.; Botelho, C. M., Nanocarriers as Active
Ingredients Enhancers in the Cosmetic Industry—The European and North America Regulation
Challenges. Molecules 2022, 27 (5).
58. Commission, E., Regulation on Cosmetic Products No 1223/2009. Commission, E., Ed. 2009.
59. FDA FDA’s Approach to Regulation of Nanotechnology Products. https://www.fda.gov/science-
research/nanotechnology-programs-fda/nanotechnology-fact-sheet (accessed 15 February 2024).
60. Ferraris, C.; Rimicci, C.; Garelli, S.; Ugazio, E.; Battaglia, L., Nanosystems in Cosmetic Products: A Brief
Overview of Functional, Market, Regulatory and Safety Concerns. Pharmaceutics 2021, 13 (9).
61. Commission, E. Regulation (EU) 2015/2283. https://eur-lex.europa.eu/legal-
content/EN/TXT/?uri=CELEX%3A02015R2283-20210327 (accessed 15 February 2024).
62. Commission, E. Regulation (EC) No 178/2002. https://eur-lex.europa.eu/legal-
content/EN/TXT/?uri=CELEX%3A02002R0178-20220701 (accessed 15 February 2024).
63. Maurya, V.; Shakya, A.; Aggarwal, M.; Gothandam, K.; Bohn, T.; Pareek, S., Fate of β-Carotene within
Loaded Delivery Systems in Food: State of Knowledge. Antioxidants 2021, 10 (3), 426.
64. Committee, E. S.; More, S.; Bampidis, V.; Benford, D.; Bragard, C.; Halldorsson, T.; Hernandez-
Jerez, A.; Hougaard Bennekou, S.; Koutsoumanis, K.; Lambre, C.; Machera, K.; Naegeli, H.;
Nielsen, S.; Schlatter, J.; Schrenk, D.; Silano Deceased, V.; Turck, D.; Younes, M.; Castenmiller, J.;
Chaudhry, Q.; Cubadda, F.; Franz, R.; Gott, D.; Mast, J.; Mortensen, A.; Oomen, A. G.; Weigel, S.;
Barthelemy, E.; Rincon, A.; Tarazona, J.; Schoonjans, R., Guidance on risk assessment of nanomaterials
to be applied in the food and feed chain: human and animal health. EFSA J 2021, 19 (8), e06768.
65. Gunawan, M.; Boonkanokwong, V., Current applications of solid lipid nanoparticles and nanostructured
lipid carriers as vehicles in oral delivery systems for antioxidant nutraceuticals: A review. Colloids and
Surfaces B: Biointerfaces 2024, 233.
66. Silva, A. C.; Santos, D.; Ferreira, D.; Lopes, C. M., Lipid-based nanocarriers as an alternative for oral
delivery of poorly water- soluble drugs: peroral and mucosal routes. Curr Med Chem 2012, 19 (26), 4495-
510.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those
of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s)
disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or
products referred to in the content.